What is MedInTech?
MedInTech is a specialized medical technology firm focused on the development of smart endoscopes designed for the digestive system. By integrating advanced imaging and sensor technology, the company provides clinicians with enhanced diagnostic capabilities, aiming to improve patient outcomes through precision medicine. The firm occupies a critical niche at the intersection of gastroenterology and digital health, positioning itself as a key innovator in minimally invasive diagnostic tools. Its market position is bolstered by a commitment to technological excellence and a clear focus on addressing the complexities of digestive health diagnostics.
How much funding has MedInTech raised?
MedInTech has raised a total of $14.6M across 1 funding round:
Series B
$14.6M
Series B (2024): $14.6M with participation from NexTrans, Hana Ventures, SL Investment Management, Industrial Bank of Korea, Atinum Investment, Futureplay, and Smilegate Investment
Key Investors in MedInTech
Atinum Investment
A principal investment firm based in Seoul that specializes in providing growth capital across various sectors, including biotechnology and life sciences.
SL Investment Management
A UK-based FCA regulated manager specializing in insurance-linked investment strategies and stable, low-correlation financial solutions.
Industrial Bank of Korea
A leading South Korean financial institution providing comprehensive banking, asset management, and loan services to small and midsized enterprises.
What's next for MedInTech?
Looking ahead, MedInTech is poised to utilize its recent capital injection to scale manufacturing capabilities and pursue regulatory approvals in key international markets. The strategic focus will likely shift toward commercialization and the integration of its smart endoscopy platforms into major hospital networks. As the company matures, the emphasis will remain on clinical validation and the continuous iteration of its hardware to maintain a competitive edge in the rapidly evolving medtech sector. Investors are expected to monitor the firm's ability to translate its technological advancements into sustained revenue growth and broader clinical adoption.
See full MedInTech company page
